Application of cytochrome P450 BM3 mutants as biocatalysts for the profiling of estrogen receptor binding metabolites of the mycotoxin zearalenone

Xenobiotica

Volumn 41, Issue 1, 2011, Pages 59-70

  Reinen, Jelle ^a   Kalma, Livia L ^a   Begheijn, Selina ^a   Heus, Ferry ^a   Commandeur, Jan N M ^a   Vermeulen, Nico P E ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Cytochrome P450 monooxygenase BM3 (P450 BM3); Estrogen receptor ; drug metabolism; High resolution screening; Xenoestrogen; Zearalenone

Indexed keywords

ALPHA ZEARALENOL; BETA ZEARALENOL; CYTOCHROME P450 BM3; DRUG METABOLITE; ESTROGEN RECEPTOR ALPHA; ZEARALENONE;

AEROBIC METABOLISM; ARTICLE; BINDING AFFINITY; BIOCATALYST; CLINICAL EVALUATION; DRUG BINDING; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME; LIVER MICROSOME METABOLISM;

BACTERIA; BIOCATALYSIS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; ESTROGEN RECEPTOR ALPHA; HUMANS; HYDROXYLATION; ISOENZYMES; MASS SPECTROMETRY; MICROSOMES, LIVER; MUTANT PROTEINS; ZEARALENONE; ZERANOL;

BACTERIA (MICROORGANISMS);

EID: 78650181536     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.525762     Document Type: Article

References (42)

1. Bennett JW, Klich M. (2003). Mycotoxins. Clin Microbiol Rev 16:497-516.
2. Berthiller F, Schuhmacher R, Buttinger G, Krska R. (2005). Rapid simultaneous determination of major type A- And B-trichothecenes as well as zearalenone in maize by high performance liquid chromatography- Tandem mass spectrometry. J Chromatogr A 1062:209-216.
3. Biehl ML, Prelusky DB, Koritz GD, Hartin KE, Buck WB, Trenholm HL. (1993). Biliary excretion and enterohepatic cycling of zearalenone in immature pigs. Toxicol Appl Pharmacol 121:152-159.
4. BryDen WL. (2007). Mycotoxins in the food chain: Human health implications. Asia Pac J Clin Nutr 16 Suppl 1:95-101.
5. Cavalieri E, Rogan E. (2006). Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: Keynote lecture. Ann N Y Acad Sci 1089:286-301.
6. Celius T, Haugen TB, Grotmol T, Walther BT. (1999). A sensitive zonagenetic assay for rapid in vitro assessment of estrogenic potency of xenobiotics and mycotoxins. Environ Health Perspect 107:63-68.
7. Charles GD, Bartels MJ, Zacharewski TR, Gollapudi BB, Freshour NL, Carney EW. (2000). Activity of benzo[a]pyrene and its hydroxylated metabolites in an estrogen receptor-alpha reporter gene assay. Toxicol Sci 55:320-326.
8. Damsten MC, de Vlieger JS, Niessen WM, Irth H, Vermeulen NP, Commandeur JN. (2008). Trimethoprim: Novel reactive intermediates and bioactivation pathways by cytochrome p450s. Chem Res Toxicol 21:2181-2187.
9. Damsten MC, Van Vugt-Lussenburg BM, ZelDenthuis T, de Vlieger JS, Commandeur JN, Vermeulen NP. (2008). Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. Chem Biol Interact 171:96-107.
10. de Vlieger JS, Kolkman AJ, Ampt KA, Commandeur JN, Vermeulen NP, Kool J, Wijmenga SS, Niessen WM, Irth H, Honing M. (2010). Determination and iDentification of estrogenic compounds generated with biosynthetic enzymes using hyphenated screening assays, high resolution mass spectrometry and offline NMR. J Chromatogr B Analyt Technol Biomed Life Sci 878:667-674.
11. Degen GH, Janning P, Wittsiepe J, Upmeier A, Bolt HM. (2002). Integration of mechanistic data in the toxicological evaluation of endocrine modulators. Toxicol Lett 127: 225-237.
12. Duca RC, Bravin F, Delaforge M, Vladescu L, Badea IA, Criste RD. (2009). Development of a new HPLC method used for determination of zearalenone and its metabolites in broiler samples. Influence of zearalenone on the nutritional properties of broiler meat. J Agric Food Chem 57:10497-10504.
13. Eiler S, Gangloff M, Duclaud S, Moras D, Ruff M. (2001). Overexpression, purification, and crystal structure of native ER alpha LBD. Protein Expr Purif 22:165-173.
14. Fink-Gremmels J. (1999). Mycotoxins: Their implications for human and animal health. Vet Q 21:115-120.
15. Hu Y, Kupfer D. (2002). Metabolism of the endocrine disruptor pesticide-methoxychlor by human P450s: Pathways involving a novel catechol metabolite. Drug Metab Dispos 30: 1035-1042.
16. Katzenellenbogen BS, Katzenellenbogen JA, Mordecai D. (1979). Zearalenones: Characterization of the estrogenic potencies and receptor interactions of a series of fungal beta-resorcylic acid lactones. Endocrinology 105:33-40.
17. Kleinova M, Zöllner P, Kahlbacher H, Hochsteiner W, Lindner W. (2002). Metabolic profiles of the mycotoxin zearalenone and of the growth promoter zeranol in urine, liver, and muscle of heifers. J Agric Food Chem 50:4769-4776.
18. Kool J, Ramautar R, Van Liempd SM, Beckman J, de Kanter FJ, Meerman JH, Schenk T, Irth H, Commandeur JN, Vermeulen NP. (2006). Rapid on-line profiling of estrogen receptor binding metabolites of tamoxifen. J Med Chem 49:3287-3292.
19. Krska R, Baumgartner S, Josephs R. (2001). The state-of-the-art in the analysis of type-A and -B trichothecene mycotoxins in cereals. Fresenius J Anal Chem 371:285-299.
20. Le Guevel R, Pakdel F. (2001). Assessment of oestrogenic potency of chemicals used as growth promoter by in-vitro methods. Hum Reprod 16:1030-1036.
21. Malekinejad H, Maas-Bakker R, Fink-Gremmels J. (2006). Species differences in the hepatic biotransformation of zearalenone. Vet J 172:96-102.
22. Malekinejad H, Maas-Bakker RF, Fink-Gremmels J. (2005). Enzyme kinetics of zearalenone biotransformation: PH and cofactor effects. Arch Toxicol 79:547-553.
23. Mirocha CJ, Pathre SV, Robison TS. (1981). Comparative metabolism of zearalenone and transmission into bovine milk. Food Cosmet Toxicol 19:25-30.
24. Nahoum V, Gangloff A, Shi R, Lin SX. (2003). How estrogen-specific proteins discriminate estrogens from androgens: A common steroid binding site architecture. FASEB J 17:1334-1336.
25. Olsen M, Kiessling KH. (1983). Species differences in zearalenone- Reducing activity in subcellular fractions of liver from female domestic animals. Acta Pharmacol Toxicol (Copenh) 52: 287-291.
26. Olsen M, Pettersson H, Kiessling KH. (1981). Reduction of zearalenone to zearalenol in female rat liver by 3 alpha-hydroxysteroid dehydrogenase. Acta Pharmacol Toxicol (Copenh) 48: 157-161.
27. Olsen M, Pettersson H, Sandholm K, Visconti A, Kiessling KH. (1987). Metabolism of zearalenone by sow intestinal mucosa in vitro. Food Chem Toxicol 25:681-683.
28. Pfeiffer E, Heyting A, Metzler M. (2007). Novel oxidative metabolites of the mycoestrogen zearalenone in vitro. Mol Nutr Food Res 51:867-871.
29. Pfeiffer E, Hildebrand A, Damm G, Rapp A, Cramer B, Humpf HU, Metzler M. (2009). Aromatic hydroxylation is a major metabolic pathway of the mycotoxin zearalenone in vitro. Mol Nutr Food Res 53:1123-1133.
30. Reeves CD, Hu Z, Reid R, Kealey JT. (2008). Genes for the biosynthesis of the fungal polyketides hypothemycin from Hypomyces subiculosus and radicicol from Pochonia chlamydosporia. Appl Environ Microbiol 74:5121-5129.
31. Reinen J, Ferman S, Vottero E, Vermeulen NPE, Commandeur JNM. (2010). Application of a fluorescence-based continuous-flow bioassay to screen for diversity of cytochrome P450 BM3 mutant libraries. J Biomol Screen (In Press).
32. Sawayama AM, Chen MM, Kulanthaivel P, Kuo MS, Hemmerle H, Arnold FH. (2009). A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds. Chemistry 15:11723-11729.
33. Shier WT, Shier AC, Xie W, Mirocha CJ. (2001). Structure-activity relationships for human estrogenic activity in zearalenone mycotoxins. Toxicon 39:1435-1438.
34. Takemura H, Shim JY, Sayama K, Tsubura A, Zhu BT, Shimoi K. (2007). Characterization of the estrogenic activities of zearalenone and zeranol in vivo and in vitro. J Steroid Biochem Mol Biol 103:170-177.
35. Tsuchiya Y, Nakajima M, Yokoi T. (2005). Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 227:115-124.
36. Ueno Y, Tashiro F. (1981). alpha-Zearalenol, a major hepatic metabolite in rats of zearalenone, an estrogenic mycotoxin of Fusarium species. J Biochem 89:563-571.
37. Välimaa AL, Kivistö AT, Leskinen PI, Karp MT. (2010). A novel biosensor for the detection of zearalenone family mycotoxins in milk. J Microbiol Methods 80:44-48.
38. Van Liempd SM, Kool J, Niessen WM, Van Elswijk DE, Irth H, Vermeulen NP. (2006). On-line formation, separation, and estrogen receptor affinity screening of cytochrome P450-derived metabolites of selective estrogen receptor modulators. Drug Metab Dispos 34:1640-1649.
39. Van Lipzig MM, Commandeur JN, de Kanter FJ, Damsten MC, Vermeulen NP, Maat E, Groot EJ, Brouwer A, Kester MH, Visser TJ, Meerman JH. (2005). Bioactivation of dibrominated biphenyls by cytochrome P450 activity to metabolites with estrogenic activity and estrogen sulfotransferase inhibition capacity. Chem Res Toxicol 18:1691-1700.
40. Zinedine A, Soriano JM, Moltó JC, Mañes J. (2007). Review on the toxicity, occurrence, metabolism, detoxification, regulations and intake of zearalenone: An oestrogenic mycotoxin. Food Chem Toxicol 45:1-18.
41. Zöllner P, Berner D, Jodlbauer J, Lindner W. (2000). Determination of zearalenone and its metabolites alpha- And beta-zearalenol in beer samples by high-performance liquid chromatographytandem mass spectrometry. J Chromatogr B Biomed Sci Appl 738:233-241.
42. Zöllner P, Jodlbauer J, Kleinova M, Kahlbacher H, Kuhn T, Hochsteiner W, Lindner W. (2002). Concentration levels of zearalenone and its metabolites in urine, muscle tissue, and liver samples of pigs fed with mycotoxin-contaminated oats. J Agric Food Chem 50:2494-2501.